Medical Devices: Reducing Import Dependence Through Manufacturing
PLI incentives and localisation are building a domestic medical-device base in a heavily import-dependent market.
Market Size
~$14–15 Bn (India, FY26E)
Growth
~15% CAGR (FY26–30E)
Read
6 min
Updated
Jun 2026
Overview
India's medical-device market is large and growing but heavily import-dependent, spanning consumables, diagnostics equipment, implants, imaging and patient monitoring. Government PLI schemes and medical-device parks aim to localise manufacturing and reduce import reliance. Rising healthcare access, insurance and an ageing population expand device demand.
The nearer-term localisation wins are in consumables and lower-complexity devices, while high-end imaging and implants remain import-led. Regulatory formalisation under the medical-device rules is professionalising the sector and raising quality standards. Domestic champions are emerging in diagnostics equipment, cardiac devices and consumables.
The opportunity blends import-substitution and structural demand growth, but competing with established global majors on high-end technology is challenging. Localisation success depends on quality, scale and clinical acceptance.
Illustrative projection from the report's stated market size (~$14–15 Bn (India, FY26E)) and growth (~15% CAGR (FY26–30E)).
Key Highlights
- Heavy import dependence creating localisation opportunity
- PLI schemes and device parks supporting manufacturing
- Consumables and diagnostics as nearer-term wins
- Regulatory formalisation raising quality standards
Growth Drivers
- PLI incentives and import-substitution push
- Rising healthcare access and insurance
- Ageing population and chronic-disease burden
- Regulatory formalisation professionalising the sector
Key Players
Investment Outlook
Medical devices offer a blend of import-substitution and demand growth, with nearer-term returns in consumables and diagnostics. We favour domestic players with quality credentials and scale in localisable categories rather than those competing head-on in high-end imaging.
Key Risks
- Competition from established global majors in high-end devices
- Regulatory and clinical-acceptance hurdles
- Import dependence for key components and technology
The Neoma View
We favour device makers scaling in localisable, quality-sensitive categories; we are more cautious where domestic players must out-innovate entrenched global majors.
Talk to an advisor →All figures are indicative and for information only - not investment advice or a recommendation. Market sizes, growth rates and financial metrics are hedged estimates that vary by source and period. Please consult your advisor before investing.
More in Healthcare
Pharma & CDMO
Pharma & CDMO: India as the World's Pharmacy and Contract Partner
Generics leadership plus a China+1 shift in contract manufacturing position Indian pharma for a structural upcycle.
Hospitals & Diagnostics
Hospitals & Diagnostics: Formalising India's Care Delivery
Rising incomes, insurance and lifestyle disease burden are driving formalisation of hospital and diagnostic care.
Biotech
Biotech: Biosimilars, Vaccines and Novel Science
India's biotech strength in biosimilars and vaccines is broadening toward novel therapeutics and bio-services.